Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07465224
PHASE2
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
Sponsor: Alnylam Pharmaceuticals
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
Official title: A Randomized, Double-blind, Placebo-controlled Study Investigating the Effect of ALN-4324 on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-01-15
Completion Date
2027-05-28
Last Updated
2026-03-11
Healthy Volunteers
No
Conditions
Interventions
DRUG
ALN-4324
ALN-4324 will be administered subcutaneously (SC).
DRUG
Placebo
Placebo will be administered SC.
Locations (1)
Clinical Trial Site
Chula Vista, California, United States